2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.

Abstract

Among the purine analogs, 2-chlorodeoxyadenosine (2-CDA) is particularly effective for the treatment of hairy cell leukemia and Waldemstrom's macroglobulinemia. Both efficacy and toxicity of 2-CDA were evaluated in previously treated patients affected with chronic lymphoproliferative disorders such as low-grade non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). Thirty cases, mainly refractory, 16 affected with CLL, were included from six centers of the International Society for Chemo-Immunotherapy (IGCI). 2-CDA was administered in a 2 h i.v. infusion for 5-7 days at the standard dose of 0.1 mg/kg/day every 4 weeks. The median number of cycles was 3. Of 30 cases, eight (26.7%) achieved a complete remission (CR), nine (30%) a partial remission (PR), and two (6.7%) a minor response, while five cases (16.6%) did not respond, and six (20%) were considered early deaths. The overall response rate (CR + PR) was 56.7%, with a median response duration of 12 months (range 3-28 +) and a better response in CLL patients. Considering that the majority of patients were heavily pretreated, toxicity was acceptable, with 40% of cases not presenting any toxic effect. The main toxicity consisted in infectious complications. Based on the results of the present study, we confirm that 2-CDA is an effective drug in these lymphoproliferative disorders, suggesting its possible use either alone or in combination, also as first-line therapy.

• Authors: M Brugiatelli, B Holowiecka, A Dmoszynska, O Krieger, A Planinc-Peraica, B Labar, V Callea, F Morabito, B Jaksic, J Holowiecki, D Lutz
• Journal: Annals of hematology (Ann Hematol) Vol. 73 Issue 2 Pg. 79-84 (Aug 1996) ISSN: 0939-5555 [Print] Germany
• PMID: 8774616 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Antineoplastic Agents
• Cladribine

Topics

• Adult
• Aged
• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Bone Marrow (pathology)
• Cladribine (administration & dosage, adverse effects, therapeutic use)
• Disease-Free Survival
• Drug Resistance, Neoplasm
• Female
• Humans
• Infusions, Intravenous
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, mortality, pathology)
• Lymph Nodes (pathology)
• Lymphoma, Non-Hodgkin (drug therapy, mortality, pathology)
• Male
• Middle Aged
• Neoplasm Staging
• Survival Rate
• Time Factors